Anti-inflammatory efficacy of low-dose cyclosporin A in psoriatic arthritis. A prospective multicentre study
| Autor: | M Bräutigam, P. Mischer, H. J. Schulze, Gottfried Weidinger, Gustav Mahrle, E. G. Jung, R. E. Schopf, L. Färber |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
medicine.medical_specialty
Chemotherapy Creatinine business.industry medicine.medical_treatment Dermatology medicine.disease Ciclosporin Gastroenterology Surgery Psoriatic arthritis chemistry.chemical_compound chemistry Psoriasis Internal medicine Cyclosporin a medicine Prospective cohort study Adverse effect business medicine.drug |
| Zdroj: | British Journal of Dermatology. 135:752-757 |
| ISSN: | 0007-0963 |
| DOI: | 10.1046/j.1365-2133.1996.d01-1074.x |
| Popis: | Fifty-five patients with psoriatic arthritis were treated with a low dose of cyclosporin A (CyA) (mean dose 2.7 mg/kg per day) for a period of 6 months to investigate the efficacy of CyA on disease parameters. Significant improvement in the joint complaints and inflammation parameters was observed including a decrease in the number of painful (-46%) and swollen (-45%) joints, tenderness (Ritchie Index : -50%) and degree of swelling (-46%), patient's assessment of pain (-35%), the duration of morning joint stiffness (-37%), as well as a decrease in C-reactive protein (-52%). A 50% reduction of joint complaints required a total of 24 weeks, whereas a 50% reduction of skin involvement was achieved after 5-6 weeks of treatment. Four patients left the study due to adverse events : creatinine level increase in two patients, hypertension in one patient and gastroenteritis in the fourth patient. Joint scintigraphy in 18 patients indicated an improvement or stable condition in 61% of cases after a mean follow-up of approximately 8 months. The results of this prospective study show that low-dose CyA effectively improves not only skin lesions, but also joint complaints in psoriatic arthritis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text